News

August 6, 2025. Deep Rx Inc. Appoints Dr. Stanley Marks to Board of Directors. We are honored to announce that Dr. Stanley M. Marks, Chairman of UPMC Hillman Cancer Center and a nationally recognized leader in oncology, has joined our Board of Directors. Dr. Marks brings decades of expertise in cancer care, research, and innovation, and will help guide the market adoption of COLOXIS, our AI-powered chemotherapy drug-selection tool for colorectal cancer patients.

The full press release is available on Newswire.

March 26, 2025. Deep Rx supported by Google Cloud Startup Program. Deep Rx has now joined the Google for Startups Cloud Program, unlocking access to advanced Google Cloud credits, developer-friendly technology, and specialized AI resources. This collaboration will empower us to accelerate our research, enhance product deployment, and strengthen cybersecurity and data protection as we scale our AI solutions for precision oncology globally.

The full press release is available on Newswire.

March 11, 2025.  Deep Rx Inc. Appoints Mr. Wensheng Fan as CEO. We are excited to announce the appointment of Wensheng Fan as our new Chief Executive Officer at DeepRx. With over 30 years of experience driving high-tech innovation, including leading Spectral AI through a successful IPO and securing significant federal and commercial funding, Mr. Fan brings a wealth of expertise to our team.

The full press release is available on Newswire.

October 1st, 2024.  DeepRx received angel seed round funding from the AI Oncology SPV.  We proudly announce that a special purpose vehicle (SPV) consisting of practicing oncologist investors has invested in the DeepRx seed round to support the validation study of the COLOXIS model for enhancing clinical outcomes of colon cancer patients. We are particularly proud of the explicit support given by the oncologists who foresee the important roles of AI in oncology practice.

April 16, 2024.  Deep Rx team is awarded an NSF I-Corp grant supporting the market analyses and business development. 

• Feb 6, 2024.  Our article on developing and validating Deep Rx COLOXIS signature for predicting oxaliplatin benefit is published by the Journal of Clinical Oncology: https://ascopubs.org/doi/10.1200/JCO.23.01080.  The NRG Oncology, a national clinical trial organization for managing large clinical trials, also published a press release highlighting this impactful work. As the first predictive AI model for oxaliplatin benefit, the COLOXIS signature will significantly improve the accuracy of colon cancer (CC) adjuvant therapies, as shown in the diagram.  It will double the response rate to oxaliplatin in the COLOXIS-positive group patients and, on the other hand, save half of patients from unnecessary oxaliplatin-induced neural toxicity.  This will impact close to a million patients worldwide. 

• May, 2022.  The abstract of our study of using Deep Rx COLOXIS system to guide regimen selection for adjuvant therapy of colon cancer is published in ASCO 2022. The significance of this work is two-fold: First, if applied in practice, the system potentially can improve clinical outcomes of over a million colorectal cancer patients worldwide. Second, this study provides the first evidence that AI methods can be used to predict efficacy of chemotherapy and biological drugs in a real clinical setting.  Since chemo drugs remain the backbone of contemporary oncology, this study opens the new direction of developing more AI models to guide application of more chemotherapy agents to treat different cancers, which will benefit millions of patients.